The National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) has qualified two sites in South Jersey from Fox Chase Cancer Center as part of its Affiliate Research Project (ARP). The qualification of these sites enhances the region’s capacity for clinical research and development.
Virtua, under the direction of Principal Investigator, Michael Entmacher, MD, includes Hematology Oncology Associates of South Jersey, Mt. Holly, NJ, and Comprehensive Cancer and Hematology Specialists, Voorhees, NJ.
South Jersey Healthcare, under the direction of PI Kush Sachdeva, MD, includes Southern Oncology-Hematology Associates, P.A. and South Jersey Radiation Oncology, P.C., both in Vineland, NJ. In addition, the Minniti Center for Medical Oncology & Hematology in Mickleton, NJ also qualified.
Virtua and South Jersey Healthcare will have access to new and innovative cancer drugs for their patients in collaboration with NCCN Member Institutions, and Principal Investigators of NCCN-funded studies will have access to NCCN-qualified community sites.
The mission of the NCCN ARP is to improve patient outcomes and to advance medical science through clinical research conducted through collaboration among the National Comprehensive Cancer Network, the 21 NCCN Member Institutions, and their community-based affiliate networks. The NCCN ARP plans to approve additional sites this year to potentially support more than 50 actively enrolling ORP trials.
‘To date, the NCCN ORP has received more than $36 million in research grants from pharmaceutical and biotech companies to support investigator- initiated trials including, but not limited to, evaluation of innovative regimens, mechanism of action, and exploration of extended uses for specific agents.
“We are delighted with the addition of community affiliates. The qualification of these sites will not only enhance studies through the diversification of patient cohorts, but also expedite accrual so that important research questions can be answered in a timely manner”, said Diane Paul, Vice President of the Oncology Research Program.